Lixte terminates unused $10M at-the-market sales agreement with WestPark Capital

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Terminated ATM agreement dated Sept 20, 2021; no sales were ever made under it.
Agreement allowed sale of up to $10M of common stock through WestPark Capital.
Termination effective May 9, 2023; no financial impact or penalty noted.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LIXTE BIOTECHNOLOGY HOLDINGS, INC. terminated Sales Agreement with WestPark Capital, Inc. valued at up to $10,000,000 (effective 2023-05-09).

Action: termination
Agreement: atm program
Counterparty: WestPark Capital, Inc.
Value: up to $10,000,000
Effective: 2023-05-09

Exact text from the filing

Item 1.02 Termination of a Material Definitive Agreement. At-the-Market Sales Agreement Effective May 9, 2023, Lixte Biotechnology Holdings, Inc. (the “Company”) terminated the at-the-market sales agreement (the “Sales Agreement”), dated September 20, 2021, with WestPark Capital, Inc. (“WestPark Capital”) relating to the possible sale of up to $10,000,000 of shares of its common stock, from time to time, through WestPark Capital.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-016006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.